Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia

Although ezetimibe has potential value as an add-on therapy to statins, it is not established whether the addition of ezetimibe to statin therapy is more effective than double-dose statin monotherapy. We conducted a crossover design study. Twenty-one coronary artery disease (CAD) patients whose lipi...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension research 2019-12, Vol.42 (12), p.1923-1931
Main Authors: Sakuma, Masashi, Toyoda, Shigeru, Hashimoto, Ryouta, Yazawa, Hiroko, Masuyama, Taiki, Hirose, Suguru, Waku, Ryutaro, Hasumi, Hisashi, Numao, Toshiyuki, Abe, Shichiro, Inoue, Teruo
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - therapeutic use
C-Reactive Protein - metabolism
Cardiovascular disease
Cholesterol
Cholesterol, LDL - blood
Coronary Artery Disease - blood
Coronary Artery Disease - complications
Coronary Artery Disease - drug therapy
Coronary vessels
Cross-Over Studies
Drug Therapy, Combination
Dyslipidemias - blood
Dyslipidemias - complications
Ezetimibe - administration & dosage
Ezetimibe - therapeutic use
Female
Health risk assessment
Hemodynamics - drug effects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypertension
Lipid Peroxidation - drug effects
Low density lipoprotein
Male
Malondialdehyde - pharmacology
Metabolic disorders
Middle Aged
Oxidative Stress
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although ezetimibe has potential value as an add-on therapy to statins, it is not established whether the addition of ezetimibe to statin therapy is more effective than double-dose statin monotherapy. We conducted a crossover design study. Twenty-one coronary artery disease (CAD) patients whose lipid profiles had not achieved Japanese guideline recommendations (JAS 2017), despite receiving low-dose statin therapy, were divided into two groups. Group A received ezetimibe 10 mg in addition to the baseline dose of statin for the first 3 months and was then switched to monotherapy with a double dose of statin for the next 3 months. Group B first received a double dose of statin for 3 months and was then switched to ezetimibe 10 mg in addition to a baseline dose of statin for the next 3 months. Compared with the baseline, double-dose statin therapy reduced low-density lipoprotein (LDL)-cholesterol (from 118 ± 22 to 104 ± 15 mg/dL, P 
ISSN:0916-9636
1348-4214
DOI:10.1038/s41440-019-0308-5